Abstract:Carmelo Laface ^ , Palma Fedele Medical Oncology, Dario Camberlingo Hospital, Francavilla Fontana, Italy ^ ORCID: 0000-0002-5074-4951. Comment on: Lim SM, Fujino T, Kim C, et al . BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res 2023;29:3004-16. Keywords: Tyrosine kinase inhibitors (TKIs); epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); osimertinib; BBT-176 Submitted Nov 29, 2023. Accepted for publication Jan 23, 2024. Published online Feb 27, 2024. doi: 10.21037/tlcr-23-795 Lung cancer holds the record in terms of cancer-related mortality in the world; non-small cell lung cancer (NSCLC) is the most frequent subtype (1). For many years, platinum-based chemotherapy has represented the only therapeutic strategy for advanced NSCLC patients although with a poor survival benefit (2). In the last decade, some NSCLC oncogenic drivers were discovered, and consequently, new targeted drugs were developed providing an impressive amelioration of overall survival (OS) for selected patients. The epidermal growth factor receptor (EGFR) gene mutations are the most important oncogenic drivers (1). In fact, several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) became standard therapies for NSCLC patients with activating EGFR gene mutations. The EGFR gene encodes for a membrane tyrosine kinase receptor whose stimulation leads to the activation of various downstream signaling pathways that regulate cellular proliferation, survival, and apoptosis (3). To be specific, EGFR exons 18 to 24 encode the tyrosine kinase domain of the receptor. The constitutive EGFR activation of the receptor is due to specific mutations to EGFR exons 18, 19, 20, and 21 leading to cell proliferation (4). Globally, EGFR mutations regard 10–15% of Caucasian and 30–50% of Asian NSCLC patients, more frequently women, non-smokers, and with adenocarcinoma histotype (5). Exon 19 deletion, and exon 21 L858R point mutation are the most common EGFR mutations corresponding to 85–90% of cases; they usually confer sensitivity to EGFR-TKIs treatment. The remaining mutations are called uncommon and include rare EGFR mutations and complex EGFR mutations, accounting for 10–15%; they have variable predictive values (6). In addition, it is not rare to find a combination of EGFR mutations (1). All generations of EGFR-TKIs have greatly changed the prognosis of EGFR-activating mutant NSCLC patients with. Osimertinib is a third-generation EGFR inhibitor that received its first approval for NSCLC patients who progressed during treatment with first- or second-generation EGFR inhibitors because of the occurrence of EGFR T790M-mediated resistance. Nowadays, osimertinib is the first-line therapy for advanced NSCLC patients with EGFR-activating mutations following the results of the FLAURA trial that demonstrated the superiority of this drug in terms of OS compared to previous generations of EGFR-TKIs (7). Moreover, osimertinib is actually indicated in the adjuvant setting for a period of treatment of 3 years based on the favorable data of the ADAURA trial (8). However, the clinical efficacy of osimertinib is limited due to the occurrence of acquired resistance, usually related to the development of EGFR C797S mutation [10–25% in second-line, 7% in first-line settings (1,9)]. It corresponds to a tertiary point mutation, consisting of substitution of the cysteine with serine within the adenosine triphosphate (ATP)-binding site. This change prevents the constitution of the covalent bond of osimertininb to mutant EGFR (1). Moreover, this mutation is responsible for cross-resistance to all other third-generation EGFR TKIs, such as narzartinib and rociletinib because of their similar binding models (10). Several options are being evaluated to challenge the acquired resistance to osimertinib such as catalytic kinase inhibitors with enhanced coverage (for example, BBT-176) and, allosteric kinase inhibitors (for example, JBJ-09-063) (11-13). Actually, no approved targeted therapies are available after progression on a third-generation EGFR-TKI. Thus, these patients are candidates only to chemotherapy. In fact, immunotherapy did not provide important survival benefit for oncogene-addicted NSCLC. Therefore, the development of a next-generation EGFR-TKI, able to overcome C797S mutation-related resistance is an urgent need. Lim et al. developed a novel oral, reversible, fourth-generation EGFR-TKI, called BBT-176, that was developed with the aim to inhibit triple-mutant EGFR L858R/T790M/C797S and 19Del/T790M/C797S. In particular, the authors employed recombinant EGFR proteins, and Ba/F3 cell lines, patient-derived cells and patient-derived xenografts expressing mutant EGFRs to evaluate, both in vitro and in vivo , the inhibitory activity and -Abstract Truncated-

Binding Thermodynamics of Fourth-Generation EGFR Inhibitors Revealed by Absolute Binding Free Energy Calculations

L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds

Molecular Mechanism Study of EGFR Allosteric Inhibitors Using Molecular Dynamics Simulations and Free Energy Calculations

Overcoming C797S Mutation: the Challenges and Prospects of the Fourth-Generation EGFR-TKIs.

Abstract 4668: Characterization of fourth-generation EGFR inhibitors in binding experiments with C797S mutant EGFR and cell-based assays with osimertinib-resistant non-small cell lung cancer cell lines

Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study

EGFR kinase mutations in NSCLC: Unexpected structural and kinetic insights into the mechanism of the T790M resistance mutation and its inhibition by irreversible inhibitors including HKI-272

Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Structural insights into characterizing binding sites in EGFR kinase mutants

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

Acquired Resistance to Third-Generation EGFR-TKIs and Emerging Next-Generation EGFR Inhibitors

Abstract 2210: Discovery of a novel third generation EGFR TKI and identification of its potential mechanism of resistance

Catalytic Lysine745 Targeting Strategy in Fourth-Generation EGFR Tyrosine Kinase Inhibitors to Address C797S Mutation Resistance

Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development

What the future holds: BBT-176, beyond third-generation EGFR tyrosine kinase inhibitors

A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations

Abstract 6511: BPI-520105, a highly potent, CNS-penetrant 4th generation EGFR inhibitor overcoming major EGFR resistance mutations in NSCLC

Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments

Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024)

Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation